ClinicalTrials.Veeva

Menu

Nasopharynx Microbiota Component and in Vitro Cytokines Production in Coronavirus Disease (COVID-19) (8796)

B

Başakşehir Çam & Sakura City Hospital

Status

Unknown

Conditions

Covid19

Treatments

Other: Observation

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The investigators will study nasopharunx microbiota composition, RNA sequences and in vitro cytokines production by peripheral blood cells of COVID-19 patients (both mild-moderate and severe cases) (comparing with convalescent patients and healthy controls).

Full description

The investigators will compare study parameters (basal) between mild-moderate and severe COVID-19 patients and with other study groups (i.e. convalescent and healthy controls). Nasopharunx microbiota dysbiosis, in vitro cytokines production profile, and peripheral blood flocytometric results of the four study groups will be compared.

In vitro cytokines production will be studied and compared in Nill (No antigens) and Mitojen (Cocktail of antigens) pre-prepared test tubes.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Ability to give a written consent

Exclusion criteria

  • In ability to give a written consent
  • Using of medications that affect the results of study parameters
  • Presence of malignancy or tuberculosis

Trial design

100 participants in 4 patient groups

1
Description:
Mild-Moderate COVID-19
Treatment:
Other: Observation
2
Description:
Severe COVID-19
Treatment:
Other: Observation
3
Description:
Convalsent (COVID-19)
Treatment:
Other: Observation
4
Description:
Healthy persons

Trial contacts and locations

2

Loading...

Central trial contact

Mehmet Hursitoglu, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems